The approval of Sativex is imminent. Developed by GW Pharmaceuticals, Sativex is expected to transform the market. The profile of the market will increase further by the expected mid-2006 launch of Acomplia by Sanofi-Aventis for obesity. Will a cannabinoid become the leading product for obesity? Find out in this report.
This says that the market has already grown 6.3% from 2004's revenues and growth of the market will continue over the forecast period 2005-2010. it's examines two potential markets: 1) if no comers arrive and 2)the potential value following launch of the key future products.
Five key questions this report answers are:
Is there a potentially large enough market for cannabinoids?
Which therapeutic areas are most likely to be responsive to cannabinoid products?
What is the global cannabinoid market value of today and over the next 5 years?
How will the cannabinoid market gain blockbuster status and when?
How do you overcome the regulatory and social issues medicinal cannabis use in the 7 major markets?
The report provides in-depth market analysis for current and potential products. This is the leading report in its field and cannot be ignored. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research. The study also assesses the challenges faced by potential cannabinoid companies.
Today therapeutic proteins are used to relieve patients suffering from many conditions, including:
Various cancers (Monoclonal antibodies, Interferons)
Heart attacks, strokes, cystic fibrosis, Gaucher's disease (Enzymes, Blood factors)
Diabetes (Insulin)
Anaemia (Erythropoietin)
Haemophilia (Blood clotting factors)
The leading therapeutic protein treatments in 2003 were:
Johnson & Johnson's anaemia treatment Procrit
Amgen's anaemia treatment Epogen
Schering-Plough's hepatitis treatments Intron A and Peg-Intron
The leading classes of therapeutic proteins in 2003 were:
Erythropoietins
Monoclonal antibodies
Interferons
While the top companies on the market were:
Amgen
Johnson & Johnson
Roche
With over 80 graphs and figures, plus almost 60 tables, this report represents a key tool for companies wishing to enter into or expand in the therapeutic protein market. The reader will be left with a clear idea of:
The challenges faced by the therapeutic protein market, and how these are being overcome
The current and future market leaders in terms of brand, class, category and company, covering the period 2003-2010
Therapeutic targets currently being developed in the field and who is responsible for this development
The competition that companies will face during the forecast period from current and pipeline products
For more information kindly visit: http://www.bharatbook.com/
